SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-011472
Filing Date
2022-06-10
Accepted
2022-06-10 16:03:04
Documents
12
Period of Report
2022-06-09
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K ovid-20220609.htm   iXBRL 8-K 76136
  Complete submission text file 0000950170-22-011472.txt   196606

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20220609_lab.xml EX-101.LAB 13896
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20220609_pre.xml EX-101.PRE 11363
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20220609.xsd EX-101.SCH 2458
6 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20220609_htm.xml XML 4695
Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036
Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 221008814
SIC: 2834 Pharmaceutical Preparations